ŽY•wl‰ÈŠwuÀ
i˜_•¶”­•\j Sumiyoshi Y, Hirahara F, Sakamoto S: Studies on the frequency of congenital malformations in Japan and Asian countries. Congenital Anomalies, 40: S76-S86, 2000. Gorai I, Nonaka K, Kishimoto H, Sahata H, Fujii Y, Fujita T: Cut-off values for vertebral fracture by peripheral quantitative computed tomographyipQCTjin Japanese women. Osteoporosis Int, 11ñ¹: S136-137, 2000. Gorai I, Tanaka K, Kikuchi R, Yoshikata H, Mochizuki K, Chaki O, Hirahara F: Estrogen receptor polymorphism does not predict the onset of menarche and natural menopause in healthy Japanese population. J Bone Miner Res, 15ñ¸: S490, 2000. Yamaga A, Taga M, Takahashi T, Shirai T: A case of postpregnancy osteoporosis. Eur J Obstet Gynecol Reprod Biol, 88: 107-109, 2000. Miyagi E, Kato H, Onose R, Matsusita N, Kameda Y, Nakazawa T, Okajima H, Nakayama H: Positive endometrial cytology associated with primary gastric adenocarcinomas: clinical and cytopathlogic findings in 16 patients. Int J Clin Oncol, 5: 229-235, 2000. Chaki O, Gorai I, Yoshikata H,.Kikuchi R, Hirahara F: The heterogeneity in bone mineral density and biochemical markers of bone turnover in response to hormone replacement. Osteoporosis Int, 11ñ¹: S174-175, 2000. Chaki O, Gorai I, Mochizuki K, Yoshikata H, Kikuchi R, Hirahara F: Hormone Replacement therapyiHRTjis more effective on bone mass in late postmenopausal Japanese women than in early ones. J Bone Miner Res, 15: S555, 2000. Chaki O, Yoshikata H, Kikuchi R, Nakayama M, Uchiyama Y, Hirahara F, Gorai I: The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women. J Bone Miner Res, 15: 1537-1544, 2000. Yoshida H,Sakakibara H, Ohkouchi C, Hirose M, Uemura T, Tage M, Hirahara F: Gene expression of cyclic nucleotide phosphodiesteraseiPDEjsubtypes in rat hypothalamus and their effect on GnRH secretion from GnRH neuron. Acta Obst Gynaec Jpn, 52: S490, 2000. He D, Uemura T, Funabashi T, Kondoh Y, Hirahara F, Mitsushima D: Changes in the number of GnRH and GAD67 immunoreactive cells in the peri-OVLT region of the hypothalamus in old-aged female rats. Acta Obst Gynaec Jpn, 52: S490, 2000. He D, Mitsushima D, Uemura T, Hirahara F, Funabashi T, Shinohara K, Kimura F: Effects of naloxone on the serum luteinizing hormone level and the number of Fos-positive gonadotropin-releasing hormone neurons in immature female rats. Brain Research, 858: 129-135, 2000. Arpino C, Brescianini S, Robert E, Castilla EE, Cocchi G, Cornel MC, Vigan C, Lancaster PAL, Merlob P, Sumiyoshi Y, Zampino G, Renzi C, Rosano A, Mastroiacovo P: Teratogenic effects of antiepileptic drugs: use of an international database on malformations and drug exposureiMADREjDEpilepsia, 41ñÂ: 1436-1443, 2000. Inayama Y, Shoji A, Odagiri S, Hirahara F, Ito T, Kawano N, Nakatani Y: Ditection of pulmonary metastasis of low-grade endometrial stromal sarcoma 25 years after hysterectomy. Pathol Res Pract, 196: 129-134, 2000. Ohyama M, Itani Y, Yamanaka M, Imaizumi K, Nishi T, Ijiri R, Tanaka Y: Umbilical cord ulcer : a serious in utero complication of intestinal atresia. Placenta, 21: 432-435, 2000. Vitalis EA, Costantin JL, Tsai PS, Sakakibara H, Paruthiyil S, Iiri T, Martini JF, Taga M, Choi ALH, Charles AC, Weiner RI: Role of the cAMP signaling pathway in the regulation of gonadotropin-releasing hormone secretion in GT1 cells. PNAS, 97ñ»: 1861-1866, 2000. •½Œ´ŽjŽ÷CZ‹gD—YCŽR’†”ü’qŽqC—é–ØŒbŽqC¼–{”ŽŽqC“c’†­MC’©‘qŒ[•¶C‘呺@_C´ì@®C⌳³ˆêFŠÂ‹«ƒzƒ‹ƒ‚ƒ“‚Ææ“VˆÙíDŠÂ‹«ƒzƒ‹ƒ‚ƒ“‹¤“¯Œ¤‹†ƒvƒƒWƒFƒNƒg•½¬11”N“x•ñ‘C12-21, 2000. •½Œ´ŽjŽ÷F’á—p—ÊŒoŒû”ð”D–òiƒsƒ‹j‚ÌŽg—p–@‚Æ‚»‚Ì’ˆÓ“_D`–k‹æˆãŽt‰ï•ñC159: 22-25, 2000. Z‹gD—YC•½Œ´ŽjŽ÷C⌳³ˆêF“ú–{‚Ìæ“VˆÙí‰uŠw’²¸DŠÂ‹«ƒzƒ‹ƒ‚ƒ“‹¤“¯Œ¤‹†ƒvƒƒWƒFƒNƒg•½¬11”N“x•ñ‘F107-108, 2000. Z‹gD—YF—tŽ_‚Ì_ŒoŠÇŒ‡‘¹Ç—\–hŒø‰Ê‚¨‚æ‚Ñ‚»‚Ì‘¼‚ÌŒø‰ÊD“ú–{–¢•aƒVƒXƒeƒ€Šw‰ïŽGŽC6ñ¹: 135-138, 2000. –Ø‘ºº—TC–ö‘ò˜aFC–Ø”ÒvŽœC“c“‡•q‹vCÄ“¡@Š]C‚‹´‹œ³C`@GŽ÷C´…@“ÄC‰J‹{@´C‰Á“¡—ÇŽ÷C¬¼‰pŠìC’‡‘òŒo•vC‘ºã@—DC’†ŽR—TŽ÷CŒÜ—ˆˆí—YCŽÂ’ËF’jCŠÖ’J—²•vC“ú–ì@ФC‰ª“‡OKC’·“c‹v•¶F•½¬10”N“x_“Þ쌧ŽY‰È•wl‰Èˆã‰ï@•wl‰Èˆ««Žîᇓo˜^WŒv•ñD“úŽY•w_“Þì’n•û•”‰ïŽC36: 52-57, 2000. –Γc”ŽsC•½Œ´ŽjŽ÷FŽY•wl‰Èf—ÂÆd–ŒŠO–ƒŒD•ª•؂ƖƒŒC79: 27-29, 2000. –Γc”ŽsF[ŒŒ‰t‹ÃŒÅ‚̃ƒJƒjƒYƒ€‚Æ‚»‚Ì‘ÎôƒVƒŠ[ƒY]ƒsƒ‹‚ÆŒŒ‰t‹ÃŒÅC‚»‚Ì‘ÎôD“ú–{ŽY‰È•wl‰ÈŠw‰ïŽGŽC52: 142-145, 2000. ’¬“c–«•¶C”’ˆä@ÊC—é–Ø—ŠGC‹e’nއ’ÃŽqCކ’Jß•vC‘ê“¿—YF‘å—Ê• …‹y‚Ñ”AŠÇ•Âǂ𗈂µ‚½ƒNƒ‰ƒ~ƒWƒA•t‘®Ší‰Š‚Ì‚P—áDŽY•wl‰È‚ÌŽÀÛC49: 1445-1447, 2000. ‹ß“¡–FmC•½Œ´ŽjŽ÷F”ð”D–@‚Ì‘I‘ð@«¬nŠú—«‚Ì”ð”DDŽY‰È‚Æ•wl‰Èi‘Ч†jC67: 259-263, 2000. ‹{é‰xŽqC’‡‘òŒo•vC’Å–¼DC“c’†–¾ŽqCÀè—ߎqC“c’†@–ôC™‰Y@Œ«C¬–죗ºCŒÜ—ˆˆí—YC•½Œ´ŽjŽ÷Fã”ç«—‘‘ƒŠà‚ɑ΂·‚éCAP—Ö@‚ðU‚è•Ô‚Á‚Ä|“–‰@‚É‚¨‚¯‚鎡—ìÑ|Di“ú–{•wl‰Èˆ««Žîᇉ»Šw—Ö@Šw‰ï‰ïŽjONCOLOGY & CHIMOTHERAPYC16ñ»: 272-277, 2000. ’ƒ–Ø@CCŒÜ—ˆˆí—YC‘P•û—T”üC‹e’n—¥ŽqC•½Œ´ŽjŽ÷Fƒzƒ‹ƒ‚ƒ“•â[—Ö@‚É‚æ‚蜖§“x‚Æœ‘ãŽÓƒ}[ƒJ[‚Í‘½—l‚ɕϓ®‚·‚éDOsteoporosis JapanC8: 238-241, 2000. ’ƒ–Ø@CCŒÜ—ˆˆí—YC–]ŒŽ‹v”üC‘P•û—T”üC‹e’n—¥ŽqC•½Œ´ŽjŽ÷Fœ‘ãŽÓƒ}[ƒJ[‚É‚æ‚èƒzƒ‹ƒ‚ƒ“•â[—Ö@‚¨‚æ‚ÑBisphosphonate—Ö@Žž‚Ìœ—ʂɑ΂·‚éŒø‰Ê‚Í—\‘ª‚Å‚«‚é‚©DOsteoporosis JapanC8: 105, 2000. ‹´–{@‰hC‘½‰ê—‹gFƒzƒ‹ƒ‚ƒ“•â[—Ö@‚Æ«ŠíoŒŒDŽY•wl‰ÈŽ¡—ÃC81ñ»: 357-360, 2000. ‰¡ˆä‰ÄŽqC—é–Ø@–ÒC‚“‡–M—»C¼–{‰Á‘ãC™‰Y@Œ«C—é–Ø’¼sF•ª•ØŒãangiography‚ɂĔ]ŒŒŠÇ¹k‚ª”F‚ß‚ç‚ꂽ‚Q—áD“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ï‰ïŽC37ñ¸: 26-30, 2000. “c’†@–ôC’‡‘òŒo•vC‰F“cìDCÀè—ߎqC‹{é‰xŽqCŒÜ—ˆˆí—YC•½Œ´ŽjŽ÷FPaclitaxeliTaxolj‚É‚æ‚鉻Šw—Ö@‚ʼnߕqÇ”½‰ž‚É‚æ‚éƒVƒ‡ƒbƒN‚ð‹N‚±‚µ‚½‚PÇ—áD“ú–{ŽY‰È•wl‰ÈŠw‰ïŽGŽC52ñÀ: 1379-1383, 2000. “c’†–¾ŽqC–Γc”ŽsC_“c‹`–¾C‹g“c@_C™‰Y@Œ«C’·“c‹v•¶Fæ“V«•›t‰ßŒ`¬‡•¹”DP‚̈ê—áD“ú–{ŽY‰È•wl‰ÈŠw‰ïŠÖ“Œ˜A‡’n•û•”‰ï‰ï•ñC37: 407-410, 2000. ˆä”¨âtC‰““¡•ûÆC•ž•”ŒjŽqCˆÀ“¡‹IŽqC–Γc”ŽsC‚‹´P’jC•½Œ´ŽjŽ÷FŒ‹Šj‡•¹”DP‚Ì‚R—áD“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ïŽC36: 209-213, 2000. ‹ß“¡@KC–Γc”ŽsCˆÀ“¡‹IŽqC‚‹´P’jC‘½‰ê—‹gC•½Œ´ŽjŽ÷Ff’f‚ɋꗶ‚µ‚½Still•a‡•¹”DP‚Ì‚P—áD“ú–{ŽY‰È•wl‰ÈŠw‰ïŠÖ“Œ˜A‡’n•û•”‰ï‰ï•ñC37: 19-23, 2000. ‚“‡–M—»C’ƒ–Ø@CCŒÜ—ˆˆí—YFƒGƒXƒgƒƒQƒ“‚Ƈ¬ƒXƒeƒƒCƒhDModern PhysicianC20ñ¹: 211-218, 2000. _“c‹`–¾C’¬“c–«•¶C—é–Ø—ŠGC¼–{‰Á‘ãC‹e’nއ’ÃŽqCކ’Jß•vC‘ê“¿—YF•wl‰Èˆ««ŽîᇂƊӕʂª¢“ï‚Å‚ ‚Á‚½Œã• –Œˆ««ƒŠƒ“ƒpŽî‚Ì‚Q—áD“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ï‰ïŽC36ñ¹: 43-46, 2000. ”’ˆä@ÊC’¬“c–«•¶C—é–Ø—ŠGC¼–{‰Á‘ãC‹e’nއ’ÃŽqCކ’Jß•vC‘ê“¿—YF•úü‹ÛǂƔ»–¾‚µ‚½œ”Õ“àŽîᎂ̂Q—áDŽY‰È‚Æ•wl‰ÈC67: 817-821, 2000. ×ì^—ŽqC–]ŒŽ‹v”üC‰““¡•ûÆCˆÀ“¡‹IŽqC’‡‘òŒo•vC‚‹´P’jC‘½‰ê—‹gCA‘ºŽŸ—YC•½Œ´ŽjŽ÷C’†’Js—YFä`“]ˆÚ‚𔺂Á‚½‹‘å—‘‘ƒŠà‚Ì‚P—áD“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ï‰ïŽC37ñ¸: 23-25, 2000. ‚@–Ö‰ÌF—cŽáŽ“ƒ‰ƒbƒg‚Ìgonadotropin•ª”å‚É‹y‚Ú‚·GnRH antagonistiGnRHantj‚̉e‹¿‚ɂ‚¢‚ÄD“ú–{ŽY‰È•wl‰ÈŠw‰ïŽGŽC52ñÃ: 1671-1680, 2000. ˆ¢•”ˆêŽ÷C‘½‰ê—‹gC•½Œ´ŽjŽ÷C‰Á“¡®•FFƒ}ƒEƒX—‘‚¨‚æ‚Ñ’…°‘Oãó‚É‚¨‚¯‚é_Œo×–E“ÁˆÙ“IˆêŽ_‰»’‚‘f‡¬y‘f‚Ì”­Œ»‚Æ‚»‚Ì‹@”\D“ú–{Žó¸’…°Šw‰ïŽGŽC17: 92-95, 2000. —އM•FC–î–ìŠìˆê˜YC“`“cŸ”üŽqCš¨@MŽqC–î“àŠî—TC“‡’J—fˆêC‚{Œb”üŽqC‰Í–ì‘PsC–ì––‰xŽqCA‘ºŽŸ—YFX”NŠú‘OŒã‚É‚¨‚¯‚é”畆ó‘Ԃ̕ω»‚ÆHRT‚ÌŒø‰Ê‚ɂ‚¢‚ÄD“ú–{X”NŠúˆãŠw‰ïŽGŽC8: 33-40, 2000. ‰½@“¿‹ÔC”ü’Ó‡‘åCA‘ºŽŸ—YC•½Œ´ŽjŽ÷C‹M—W•y‹vŽqF—Y«ƒ‰ƒbƒg‚É‚¨‚¯‚éGABAAŽó—e‘Ì—z«GnRHƒjƒ…[ƒƒ“”‚Ì”­’B•ω»D‘æ77‰ñ“ú–{¶—Šw‰ï‘å‰ï—\eWC212, 2000. ŒI—Ñ@–õCŠÖ@Œ«ˆêCÎì‰ë•FCÎ’Ë•¶•½Cˆäã—T”üC¡ˆäˆê•vCŠâ“c‰ÃsCA‘ºŽŸ—Y‘¼F_“Þ쌧‰º‚É‚¨‚¯‚é“àŽ‹‹¾‰ºŽèp‚ÌŒ»‹µ‚Æ‚»‚̇•¹ÇD“ú–{ŽY‰È•wl‰ÈŠw‰ï“àŽ‹‹¾Šw‰ïŽC15: 123-128, 2000. {ŽRg”üŽqCät‹´—˜–çC‹M—W•y‹vŽqC•½Œ´ŽjŽ÷CA‘ºŽŸ—YFGnRHƒjƒ…[ƒƒ“iGT1-7×–Ej‚Ì“d‹CŠˆ“®‚ɑ΂·‚éƒGƒXƒgƒƒQƒ“‚ÆNMDA‚Ì‘ŠŒÝì—pD‘½“d‹É”|—{ŽMiMEDj‚ð—p‚¢‚½ŒŸ“¢.“ú–{“à•ª”åŠw‰ïŽGŽC76: 394, 2000D {ŽRg”üŽqCät‹´—˜–çCA‘ºŽŸ—YC•½Œ´ŽjŽ÷C‹M—W•y‹vŽqFŽ‹°‰º•”•sŽ€‰»GnRHƒjƒ…[ƒƒ“iGT1-7×–Ej‚Ì“d‹CŠˆ“®‚Ì‘½“_“¯Žž‹L˜^D‘æ77‰ñ“ú–{¶—Šw‰ï‘å‰ï—\eWC212, 2000. ¼“‡³”ŽC¯“c@—²C“V–ì@Š®CˆÉ“Œ@‹œC‘å’Ë”ŽŒõC‰Á“¡—ÇŽ÷C¬¼‰p•vC匴G–çC–Γc”ŽsC‘ã“cŽ¡•FC™@r—²C‚ŽRŒc‰îC‘½˜a“c“N—YC–x@—T‰ëC‘O“céhCŽR’†”ü’qŽqC’†–ìáÁ²’jC•l“c@GF_“Þ쌧”DŽY•wŽ€–S‚ÌŒŸ“¢i1993”N`1995”Nj‚Æ”DŽY•wŽ€–S–hŽ~‘ÎôD“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ï‰ïŽC36ñ¹: 12-21, 2000. ¼‰ºŒaLC‹{é‰xŽqC¬–죗ºC‰Á“¡‹v·C’†ŽR—TŽ÷C‰ª–{’¼KFœ”ÕƒŠƒ“ƒpߊs´ŽèpŒã‚̉ºŽˆƒŠƒ“ƒp•‚Žî‚ÌŒ´ˆö‚ð’T‚éDŽY•wl‰È‚ÌŽÀÛC49: 1143-1149, 2000.
i‘@@àj •½Œ´ŽjŽ÷FIUDDŽY•wl‰È‚ÌŽÀÛC49ñÂ: 1537-1544, 2000. •½Œ´ŽjŽ÷F’†‚”N—«‚ÌQuality of lifeiQOLjDŽY•wl‰ÈŽ¡—ÃC81ñ½: 632-637, 2000. ‚‹´P’ji“ú•êˆãŽ–•´‘ˆ‘ÎôˆÏˆõ‰ï‹¤’˜jFŽq‹{ŠO”DPD“ú•ê•ÒC‚±‚ê‚©‚ç‚ÌŽY•wl‰Èˆã—ÃŽ–ŒÌ–hŽ~‚Ì‚½‚ß‚Éñ¼C2000. ‚‹´P’ji“ú•êˆãŽ–•´‘ˆ‘ÎôˆÏˆõ‰ï‹¤’˜jFíˆÊ‘Ù”Õ‘Šú”—£D“ú•ê•ÒC‚±‚ê‚©‚ç‚ÌŽY•wl‰Èˆã—ÃŽ–ŒÌ–hŽ~‚Ì‚½‚ß‚Éñ½C2000. ‚‹´P’ji“ú•êˆãŽ–•´‘ˆ‘ÎôˆÏˆõ‰ï‹¤’˜jFœ”ÕˆÊD“ú•ê•ÒC‚±‚ê‚©‚ç‚ÌŽY•wl‰Èˆã—ÃŽ–ŒÌ–hŽ~‚Ì‚½‚ß‚Éñ¾C2000. ŒÜ—ˆˆí—YFƒ‰ƒCƒtƒTƒCƒNƒ‹‚É”º‚¤œ‘ãŽÓ‚̃}ƒlƒWƒƒ“ƒgD•ÂŒoŠú‚©‚ç•ÂŒoŒãDƒzƒ‹ƒ‚ƒ“‚Æ—Õ°C2000”Nt‹G‘Ч†F123-131, 2000. ŒÜ—ˆˆí—YF•wl‰È—̈悩‚ç‚Ý‚½ƒrƒ^ƒ~ƒ“D܂ɂæ‚霑eé Ç‚ÌŽ¡—ÃDCLINICAL CALCIUMC10: 1123-1130, 2000. ŒÜ—ˆˆí—YFœ‘eé Çf—Âɂ¨‚¯‚霑ãŽÓ‘ª’莎–ò‚Ì—L—p«‚ɂ‚¢‚ÄDƒƒfƒBƒJƒ‹’©“úC29ñ¼: 16-19, 2000. ŒÜ—ˆˆí—YFŒ´”­«œ‘eé Ç‚ÌŠÇ—DŒŽŠ§•Û’c˜AC668: 59-66, 2000. ŒÜ—ˆˆí—YFƒXƒe[ƒW‚²‚Ƃ̎¡—Ö@‚Ì‘I‘ðD—Õ°‚Æ–ò•¨Ž¡—ÃC19: 976-979, 2000. ’†ŽR¹Ž÷FŠCŠO•¶Œ£Ð‰îDTHE BONEC14ñ¸: 159, 2000. ’†ŽR¹Ž÷FŠCŠO•¶Œ£Ð‰îDTHE BONEC14ñ¹: 262, 2000. ’†ŽR¹Ž÷FŠCŠO•¶Œ£Ð‰îDTHE BONEC14ñº: 388, 2000. ’†ŽR¹Ž÷FŠCŠO•¶Œ£Ð‰îDTHE BONEC14ñ»: 501, 2000. ’†ŽR¹Ž÷FŠCŠO•¶Œ£Ð‰îDTHE BONEC14ñ¼: 597, 2000. ˆÀ“¡‹IŽqCàVˆä‚©‚¨‚èC•½’m—YC•½Œ´ŽjŽ÷F—¬ŽYi‚Æ‚­‚ÉKе—¬ŽYj‚ƈâ“`ƒJƒEƒ“ƒZƒŠƒ“ƒODŽY•wl‰È‚ÌŽÀÛC49ñÄ: 1971-1979, 2000. ’¬“c–«•¶C‘½‰ê—‹gF“û`•ª”å‚Ì‘£i–@DŽY‰È‚Æ•wl‰ÈC67: 201-206, 2000. ’¬“c–«•¶C‘½‰ê—‹gF–òÜŽt‚Ì‚½‚߂̗հuÀ@‚»‚Ì31CŒŽŒoˆÙí|ŒŽŒo¢“ïÇ‚ð’†S‚É|CPharmavisionC34: 10-16, 2000. ŽR’†”ü’qŽqF”D•w‚Ì–ò•¨•ž—pDŽ¡—ÃC82ñ¾: 121-124, 2000. ŽR’†”ü’qŽqFFetus as a patient. ‚±‚Ç‚àˆã—ÃZƒ“ƒ^[ˆãŠwŽC29ñ»: 243-245, 2000. ’ƒ–Ø@CCŒÜ—ˆˆí—YFŠeŽí–ò܂̖òŒøC“Š—^•û–@C•›ì—pðBƒGƒXƒgƒƒQƒ“»ÜiSERM‚ðŠÜ‚ÞjDTHE BONEC14ñ¸: 71-77, 2000. ’ƒ–Ø@CFƒGƒXƒgƒƒQƒ“ESERMD¡ŒŽ‚ÌŽ¡—ÃC8: 916-919, 2000. ’†ŽR—TŽ÷F•wl‰ÈŠO—ˆf—ÃD—Õ°ŒŸ¸C44ñÂ: 1227-1231, 2000. ‘½‰ê—‹gC’¬“c–«•¶F1eEƒvƒƒ‰ƒNƒ`ƒ“CAnnual Review “à•ª”åC‘ãŽÓ2000C“à•ª”å@‚PDŽ‹°‰º•”|‰º‚‘ÌC204-208, 2000. ‘½‰ê—‹gC’¬“c–«•¶FŽvtŠú‚Ì“û–[”­ˆç•s‘SE‘½–ÑÇDŽY•wl‰ÈŽ¡—Ãi‘ЧjŠO—ˆf—ÃKƒCƒhC80: 413-419, 2000.
i’˜@@‘j A‘ºŽŸ—YF“û`•ª”å—}§D‘½‰ê{K’jC”öŒ`‰x˜Y‘•ÒW, 2000¡“ú‚ÌŽ¡—ÃŽwjCˆãŠw‘‰@C778-779, 2000. A‘ºŽŸ—YC‹´–{@‰hFŽYåñŠú‚ÌŠ´õÇD²“¡˜a—YC…ŒûOŽi•ÒWCƒCƒ“ƒtƒH[ƒ€ƒhEƒRƒ“ƒZƒ“ƒgƒKƒCƒ_ƒ“ƒXCŽüŽYŠú•ÒCæ’[ˆãŠwŽÐC267-273, 2000. ‚‹´P’ji“ú•êˆãŽ–•´‘ˆ‘ÎôˆÏˆõ‰ï‹¤’˜jFŠÅŒì—vˆõ‚̈ã—ÃŽ–ŒÌ–hŽ~‚Ì‚½‚ß‚ÉD“ú•êˆãŽ–•´‘ˆ‘ÎôˆÏˆõ‰ï•Ò, 2000. ŒÜ—ˆˆí—YFœ‘eé Ç‚Ìf’f‚Ì•ûjiŽY•wl‰È‚Ì—§ê‚©‚çjœ‘eé Ç‚Ìf’fŠî€DXˆä_¢•ÒC‘S–ʉü’ùœ‘eé ÇQ&ACˆã–òƒWƒƒ[ƒiƒ‹ŽÐC121-122, 127-132, 2000. ŒÜ—ˆˆí—YFœ—ÊŒ¸­‚Ì—\–hEŽ¡—ÃDœ‘eé Ç—\–hƒ}ƒjƒ…ƒAƒ‹CŒú¶È˜Vl•ÛŒ’•ŸŽƒ‹Ç˜Vl•ÛŒ’‰ÛC25-30, 104-113, 2000. ’ƒ–Ø@CFœ‹zŽûƒ}[ƒJ[CNTxD¼‘ò—Ç‹L•ÒCœ‘ãŽÓƒ}[ƒJ[Cˆã–òƒWƒƒ[ƒiƒ‹ŽÐC41-49, 2000. ’ƒ–Ø@CFŠeŽí޾г‚Æœ‘eé ÇC“à•ª”åˆÙíC«‘B‹@”\’ቺÇi—«jD“ú–{œ‘eé ÇŠw‰ï•ÒC‘±”­«œ‘eé Ç‚ÌŽ¡—Ã}ƒjƒ…ƒAƒ‹Dƒ‰ƒCƒtƒTƒCƒGƒ“ƒXŽÐC34-39, 2000. ’ƒ–Ø@CFœ‘ãŽÓƒ}[ƒJ[D“ú–{œ‘eé ÇŠw‰ï•ÒC‘±”­«œ‘eé Ç‚ÌŽ¡—Ã}ƒjƒ…ƒAƒ‹Cƒ‰ƒCƒtƒTƒCƒGƒ“ƒXŽÐC143-148, 2000. ’ƒ–Ø@CFœ‘eé Ç‚ÌŠÇ—ŽwjDƒƒfƒBƒJƒ‹’©“úC’©“úV•·ŽÐC37, 2000.
iŠw‰ï”­•\j Gorai I, Nonaka K, Kishimoto H, Sahata H, Fujii Y, Fujita T: Cut-off values for vertebral fracture by peripheral quantitative computed tomographyipQCTjin Japanese women. World Congress on Osteoporosis 2000, Cicago, 2000, 6. Gorai I, Tanaka K, Kikuchi R, Yoshikata H, Mochizuki K, Chaki O, Hirahara F: Estrogen receptor polymorphism does not predict the onset of menarche and natural menopause in healthy Japanese population. The 22nd Annual Meeting of the American Society for Bone and Mineral Research, Tronto, 2000, 9. Shigeta H, Taga M, Hiraga M, Sakakibara H, Hirahara F, Osada H: Nidogen-2 mRNA expression is enhance during decidualization in human endometrium. 11th International Congress of Endocrinology, Sydney, 2000, 10. Sakakibara H, Yoshida H, Ohkouchi C, Shigeta H, Uemura T, Taga M, Hirahara F: Gene expression of cyclic nucleotide phosphodiesteraseiPDEjsubtypes in rat hypothalamus and their effect on GnRH secretion from GnRH neuron. 11th International Congress of Endocrino-logy, Sydney, 2000, 10 Miyagi E, Nakayama H, Onose R, Kato H, Hatta M, Sugiura K, Udagawa K, Nakazawa T, Gorai I, Hirahara F: Late recurrent carcinoma of the uterine cervix. XVI FIGO World Congress of Gynecology and Obstetrics, Washing-ton D.C., 2000, 9. Chaki O, Gorai I, Yoshikata H, Kikuchi R, Hirahara F: The heterogeneity in bone mineral density and biochemical markers of bone turnover in response to hormone replacement. World Congress on Osteoporosis 2000, Chicago, 2000, 6. Chaki O, Yoshikata H, Kikuchi R, Nakayama M, Uchiyama Y, Hirahara F, Gorai I: The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women. The 22nd Annual Meeting of the American Society for Bone and Mineral Research, Toronto, 2000, 9. Udagawa K, Yasumitsu H, Esaki M, Sawada H, Nagashima Y, Aoki I, Miyagi E, Nakazawa T, Hirahara F, Miyazaki K, Miyagi Y: Cellular localization of PP5iplacental protein 5j/TFPI-2itissue factor pathway inhibitor-2jin human placent; a possible role of PP5/TFPI-2 as an anti-coagulant on surface of syncytiotrophoblatsts. XVI FIGO World Congress of Gynecology and Obstetrics, Washington D.C., 2000, 9. Yoshida H, Sakakibara H, Ohkouchi C, Hirose M, Uemura T, Taga M, Hirahara F: Gene expression of cyclic nucleotide phosphodiesteraseiPDEjsubtypes in rat hypothalamus and their effect on GnRH secretion from GnRH neuron. 52nd annual meeting of Japan society of obstetrics and gynecology, Tokushima, 2000, 4. He D, Uemura T, Funabashi T, Kondoh Y, Hirahara F, Mitsushima D: Change in the number of GnRH and GAD67 immunoreactive cells in the peri-OVLT region of the hypothalamus in old-aged female rats. 52nd annual meeting of Japan society of obstetrics and gynecology, Tokushima, 2000, 4. Hiraga M, Shigeta H, Taga M, Sakakibara H, Osada H, Hirahara F: Enhanced ezpression of MxA mRNA in human decidua. 11th International Congress of Endocrino-logy, Sydney, 2000, 10. •½Œ´ŽjŽ÷F’á—p—ʃsƒ‹‚ÌŽg—p•û–@‚Æ‚»‚Ì’ˆÓ“_D`–k‹æˆãŽt‰ïŠwpW‰ïC‰¡•lC2000, 1. •½Œ´ŽjŽ÷F‚ª‚ñŒ¤‹†‚ÆŽ¡—ÂÌÅ‘Oü|—«‚Ì‚ª‚ñ|‚ª‚ñ‚̕“Iˆã—Âð‚ß‚´‚µ‚ÄD‰¡•lŽs‘僊ƒJƒŒƒ“ƒguÀC‰¡•lC2000, 1. •½Œ´ŽjŽ÷F•wl‰Èˆ««Žîᇂɑ΂·‚éŋ߂̎¡—Ö@D“ú–{’Z”g•ú‘—C“Œ‹žC2000, 1. •½Œ´ŽjŽ÷F—«‚ª’ˆÓ‚·‚ׂ«‚ª‚ñ|Œ’N’m‚肽‚¢˜bCƒ‰ƒWƒI“ú–{C“Œ‹žC2000, 2. •½Œ´ŽjŽ÷F¶—•s‡Ci¶—’Éj‚ÆŒ’N|Œ’N’m‚肽‚¢˜bCƒ‰ƒWƒI“ú–{C“Œ‹žC2000, 2. •½Œ´ŽjŽ÷Fƒsƒ‹C”ð”D‚ð‚ß‚®‚Á‚Ä|Œ’N’m‚肽‚¢˜bCƒ‰ƒWƒI“ú–{C“Œ‹žC2000, 2. •½Œ´ŽjŽ÷F’†‚”N—«‚ÌŒ’N|Œ’N’m‚肽‚¢˜bCƒ‰ƒWƒI“ú–{C“Œ‹žC2000, 2. •½Œ´ŽjŽ÷FŠÂ‹«ƒzƒ‹ƒ‚ƒ“‚Ææ“VˆÙíD‰¡•lŽs—§‘åŠwŠÂ‹«ƒzƒ‹ƒ‚ƒ“Œ¤‹†Ž{ÝŠJÝ‹L”OCŠÂ‹«ƒzƒ‹ƒ‚ƒ“Œ¤‹†•ñ‰ïC‰¡•lC2000, 3. •½Œ´ŽjŽ÷F¶BˆÙ•ς͡|æ“VˆÙ탂ƒjƒ^ƒŠƒ“ƒO‚Ì‹•‘œ‚ÆŽÀ‘œ|D‘æ102‰ñõF‘ÌŒ¤‹†‰ïC“Œ‹žC2000, 6. •½Œ´ŽjŽ÷CZ‹gD—YCŽR’†”ü’qŽqC—é–ØŒbŽqC¼–{”ŽŽqC’©‘qŒ[•¶C“c’†­MC‘呺@_C´ì@®C‘OŒ´‘åìC⌳³ˆêF“ú–{•ê«•ÛŒìŽY•wl‰Èˆã‰ïæ“VˆÙ탂ƒjƒ^ƒŠƒ“ƒO’²¸‚©‚ç|–{–M‚É‚¨‚¯‚éæ“V«SŒŒŠÇˆÙí”­¶‚ÌŒ»‹µ|D‘æ40‰ñ“ú–{æ“VˆÙíŠw‰ïŠwpW‰ïC¼]C2000, ‚V. •½Œ´ŽjŽ÷F‚ª‚ñ‚̕“Iˆã—Âð‚ß‚´‚µ‚Ä|¡“ú‚Ì—‘‘ƒ‚ª‚ñŽ¡—Ã|D‘æ42‰ñ_“ÞìˆãŠw‰ï‘‰ïC‰¡•lC2000, 11. A‘ºŽŸ—YFŽq‹{“à–ŒÇD“¡‘òƒP[ƒuƒ‹ƒeƒŒƒruƒ`ƒƒƒ“ƒlƒ‹‚Ó‚¶‚³‚í20vC“¡‘òC2000, 6. ‚‹´P’jFŽY•wl‰Èˆã—ẪCƒ“ƒtƒH[ƒ€ƒhEƒRƒ“ƒZƒ“ƒg|’鉤؊JD‘æ11‰ñ“ú•ê‘S‘Žx•”ˆãŽ–•´‘ˆ‘Îô’S“–ŽÒ˜A—‰ïC“Œ‹žC2000, 11. ‚‹´P’jFŽY‰ÈŠÅŒì—vˆõ‚ÌƒŠƒXƒNƒ}ƒl[ƒWƒƒ“ƒg|ˆãŽ–•´‘ˆ‚ÌŽÀ—áD‘æ18‰ñ_“Þ쌧ŽY‰ÈŠÅŒì—vˆõŒ¤C‰ïC‰¡•lC2000, 12. ŒÜ—ˆˆí—YFŒ’N‚Ù‚Á‚ƃ‰ƒCƒ“Duœ‘eé Ç‚Ì”Y‚ÝvCNHKƒeƒŒƒr@BS2C“Œ‹žC2000, 1. ŒÜ—ˆˆí—YC‹e’n—¥ŽqC‘P•û—T”üC’ƒ–Ø@CC•½Œ´ŽjŽ÷Fƒrƒ^ƒ~ƒ“DŽó—e‘̈â“`Žq‘½Œ^‚Í‘ŠŒÝ‚ÉŠÖ˜A‚µ‚ĕŒoŒã—«‚Ìœ—ʒቺ‚ɉe‹¿‚ð—^‚¦‚éD‘æ52‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ïC“¿“‡C2000, 4. ŒÜ—ˆˆí—YF“Á•Êu‰‰@Œ´”­«œ‘eé Ç‚ÌŠÇ—D‘æ378‰ñ_“Þ쌧•ÛŒ¯ˆã‹¦‰ïŒŽ—ጤ‹†‰ïC‰¡•lC2000, 4. ŒÜ—ˆˆí—YF“Á•Êu‰‰@•ÂŒoŒãœ‘eé Ç‚ÌŠÇ—D•½¬12”N“x“ú–{•ê«•ÛŒìŽY•wl‰Èˆã쌧Žx•”E“ú–{ŽY‰È•wl‰ÈŠw‰ïì’n•û•”‰ï‡“¯Šwpu‰‰‰ïC‚¼C2000, 6. ŒÜ—ˆˆí—YF“Á•Êu‰‰@Œ´”­«œ‘eé Ç‚ÌŠÇ—D‰¡•lŽs£’J‹æˆãŽt‰ïŠwpu‰‰‰ïC‰¡•lC2000, 7. ŒÜ—ˆˆí—YFƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[@œ‘ãŽÓƒ}[ƒJ[‚Ì—Õ°‰ž—pD‘æ18‰ñ“ú–{œ‘ãŽÓŠw‰ïCL“‡C2000, 7. ŒÜ—ˆˆí—YFŒ’N‚Ù‚Á‚ƃ‰ƒCƒ“Duœ‘eé Ç‚Ì—\–h‚ÆŽ¡—ÃvCNHKƒeƒŒƒr@BS2C2000, 9. ŒÜ—ˆˆí—YFƒVƒ“ƒ|ƒWƒEƒ€‚Q@uœ‘eé Çf—Âɂ¨‚¯‚霑ãŽÓƒ}[ƒJ[‚Ì“K³Žg—pvœ—ÊŒ¸­‚©‚ç‚Ý‚½ƒJƒbƒgƒIƒt’l‚Ì’ñˆÄD‘æ‚Q‰ñ“ú–{œ‘eé ÇŠw‰ïCH“cC2000,10. ŒÜ—ˆˆí—YF“Á•Êu‰‰@Œ´”­«œ‘eé Ç‚ÌŠÇ—DŠC˜V–¼ŽsˆãŽt‰ïŠwpu‰‰‰ïCŠC˜V–¼C2000, 11. ”’{˜a—TFf—ÕñV‰ü’ù‚ɂ‚¢‚ÄD_“ÞìŽY‰È•wl‰Èˆã‰ï“`’BuK‰ïC‰¡•lC2000, 3. ”’{˜a—TF•½¬12”N“xf—ÕñV‰ü’ù‚É‚ ‚½‚Á‚ÄD‰¡•lŽY•wl‰Èˆã‰ïŒ¤‹†‰ïC‰¡•lC2000, 4. ”’{˜a—TFŽq‹{“à–ŒÇ‚Ìf’fŠî€‚ÆŽ¡—Õû–@DƒXƒvƒŒƒLƒ…ƒAMP1.8u‰‰‰ïC‰¡•lC2000, 10. ”’{˜a—TFÅV‚ÌŽq‹{“à–ŒÇ‚Ì—Õ°Cf’fi‚»‚Ì‚PjD‘æ‚T‰ñ_“Þ쌧¼•”ŽY•wl‰ÈŒ¤C‰ïCŒú–ØC2000, 11. –Ñ—˜@‡Ff’f¥Ž¡—Âɋꗶ‚µ‚½‚PÇ—áD‘æ‚P‰ñÓì’n‹æ•a‰@ŽY•wl‰ÈŒ¤‹†‰ïC“¡‘òC2000, 2. –Ñ—˜@‡C‘åŽRrŽ÷C‹ß“¡@KCA‘ºŽŸ—YFŽq‹{Œã•ǂɋ‘勨Žî‚ð‡•¹‚µ’éØŒã[•”Ö¬ŒŒð‚ƂȂÁ‚½ˆêÇ—áD‘æ348‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ïC‰¡•lC2000, 5. –Ñ—˜@‡F“–‰@‚É‚¨‚¯‚é‘o‘Ù•ª•؂ɂ‚¢‚ÄD“¡‘ò’n‹æŽüŽYŠúŒ¤‹†‰ïC“¡‘òC2000, 10. –Ø‘ºº—TC‰J‹{@´C‰Á“¡—ÇŽ÷C¬¼‰pŠìC–Ø”ÒvŽœCÖ“¡Š]C´…@“ÄC‚‹´‹œ³C“c“‡•q‹vC’‡‘òŒo•vC’†ŽR—TŽ÷C`@GŽ÷C‘ºã@—DC–ö‘ò˜aFC’·“c‹v•¶CZ‹gD—YF•½¬11”N“x_“Þ쌧ŽY‰È•wl‰Èˆã‰ï@•wl‰Èˆ««Žîᇓo˜^WŒv•ñD‘æ349‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ïC‘Š–ÍŒ´C2000, 7. ˆÀ“¡‹IŽqF“à•ª”å‹@”\ޏ’²‚Æ•sˆçÇD‘æ45‰ñ“ú–{•s”DŠw‰ïC_ŒËC2000, 11. ˆÀ“¡‹IŽqF–¾“ú‚Ì•sˆçÇf—ÂÖ|“à•ª”å‹@”\ޏ’²‚Æ•sˆçÇ|D‘æ46‰ñ“ú–{•s”DŠw‰ï‘‰ïC“Œ‹žC2000, 11. ’r“c–œ—¢˜YCç–Ø–ì‚Ý‚íCÎì‰ë•FC‹ß“¡–FmC‘º£^—ŽqC•½Œ´ŽjŽ÷C²“¡‰Ã•ºFVitrification–@‚ð—p‚¢‚½ƒ}ƒEƒX—‘‘ƒ‘gD‚Ì“€Œ‹•Û‘¶‚ÉŠÖ‚·‚錟“¢D‘æ15‰ñ¶B–ƉuŠw‰ïC“Œ‹žC2000, 12. ¬–죗ºC¼‰ºŒaLC‹{é‰xŽqC‰Á“¡‹v·C’†ŽR—TŽ÷FisŽq‹{èòŠà•úŽËüŽ¡—×á‚Ì—\ŒãˆöŽqŒŸ“¢D‘æ52‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ïC“¿“‡C2000, 4. ¬–죗ºC”ª“c[ŽqC™‰Y@Œ«C‰Á“¡‹v·C’†ŽR—TŽ÷FŽq‹{‘Ì•”Ÿ÷‰t«‘BŠà10—á‚Ì—Õ°×–EŠw“IŒŸ“¢D‘æ14‰ñ“ú–{—Õ°×–EŠw‰ïŠÖ“Œ˜A‡‰ïC‰¡•lC2000, 9. ’¬“c–«•¶C•ˆä”üéC—é–Ø—ŠGC‹e’nއ’ÃŽqC‘òˆä‚©‚¨‚èC‘ê“¿—YFŽq‹{“Eo‚É‚æ‚èhCG‚̉A«‰»‚ª”F‚ß‚ç‚ꂽ—Õ°“IãO–ÑŠà‚Ì‚P—áD‘æ100‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠÖ“Œ˜A‡’n•û•”‰ï‘‰ïC‘å‹{C2000, 10. ŽR’†”ü’qŽqC‚‹´P’jC²“¡Œ[Ž¡F•½¬10”N“x_“Þ쌧ŽüŽYŠúˆã—Ã’²¸•ñD‘æ345‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ïC‰¡•lC2000, 1. ŽR’†”ü’qŽqCZ‹gD—YC•½Œ´ŽjŽ÷C“c’†­MC’©‘qŒ[•¶C‘呺@_C´ì@®C‘OŒ´‘åìC⌳³ˆêF“ú–{‚É‚¨‚¯‚é‚”NoŽY‚Ææ“VˆÙí|“ú–{•ê«•ÛŒìŽY•wl‰Èˆã‰ïæ“VˆÙ탂ƒjƒ^ƒŠƒ“ƒO’²¸‚ð’†S‚É|D•ª•ØŠÇ—Œ¤‹†‰ïC2000, 7. ŽR’†”ü’qŽqC•½’m—YC󌩭rCÂŽR”ü‰ÁC²Ž¡°ÆC‘åŽR–qŽqC’–’J‘׎jCŒã“¡²ŽqC‘å•l—pŽC¼ŽõŽ¡C“c’†—S‹gF“Ë‘R‚ÌŽq‹{“àä`‘ÑoŒŒ‚𗈂µ‚½æ“V«ã•”Á‰»ŠÇ•½ǂ̂V—áD‘æ36‰ñ“ú–{V¶Ž™Šw‰ïƒ[ƒNƒVƒ‡ƒbƒvC2000, 7. ŽR’†”ü’qŽqC‚‹´P’jC²“¡Œ[Ž¡F_“Þ쌧ŽüŽYŠú‹¦‹c‰ïŽüŽYŠúˆã—Ã’²¸•ñ@_“Þ쌧ŽüŽYŠú‹~‹}ƒVƒXƒeƒ€‚É‚¨‚¯‚é”À‘—Œ³’²¸|•½¬8`10”N“xŽÀÑ|D‘æ351‰ñ_“Þ쌧ŽY•wl‰È’n•û•”‰ïC‰¡•lC2000, 11. 匴G–çC‹g“c@_C‘å‰Í“àç’ߎqC•–ØŒbŽqC‘½‰ê—‹gC•½Œ´ŽjŽ÷Fƒ}ƒEƒXŽ‹°‰º•”GnRHŽY¶×–EŠ”CGTI×–E‚É‚¨‚¯‚égalaninŽó—e‘̂̈â“`Žq”­Œ»D‘æ52‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ïC“¿“‡C2000, 4. •½’m—YC²Ž¡°ÆCŠâ‹´˜aŽqCÂŽR”ü‰ÁC󌩭rCŽR’†”ü’qŽqF•ê‘Ì”À‘—‚̃^ƒCƒ~ƒ“ƒO|’áo¶‘ÌdŽ™‚ª•Øo‚³‚ê‚éŠëŒ¯‚ª‚ ‚éê‡|IUGRDŽY‰È‹~‹}˜A—‰ïC‰¡•lC2000, 3. •½’m—YCÂŽR”ü‰ÁCŽR’†”ü’qŽqF_“Þ쌧—§‚±‚Ç‚àˆã—ÃZƒ“ƒ^[‚É‚¨‚¯‚é”DP‘OŠO—ˆ‚ÌŽŽ‚ÝD‘æ24‰ñ“ú–{—Õ°ˆâ“`Šw‰ïC‘åãC2000, 5. •½’m—YCŽR’†”ü’qŽqF“ûâô‹¹…‚ÌŒZ’í—áD‘æ45‰ñ“ú–{l—Þˆâ“`Šw‰ïC•Ÿ‰ªC2000, 10. ŽR‰ê–¾OF”DP––Šú‚Ìp‘OƒPƒg[ƒVƒX‚ÉŠÖ‚·‚錟“¢D‘æ52‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ïC“¿“‡C2000, 4. ‘åŽRrŽ÷C’·£Š°”üC–Ñ—˜@‡CA‘ºŽŸ—YFŽq‹{E—‘‘ƒŽîᇂƂ̊ӕʂª¢“ï‚Å‚ ‚Á‚½œ”Õ“àŽîᇂ̂QÇ—áD‘æ352‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ïC‰¡•lC2000, 12. Îì_ŽjC‹ß“¡@KCt–Ø@“ÄCˆÀ“¡‹IŽqC‚‹´P’jC‰““¡•ûÆC•½Œ´ŽjŽ÷F“–‰@‚É‚¨‚¯‚éHIV—z«”D•w‚ÌŽæ‚舵‚¢ó‹µD‘æ100‰ñ“ú–{ŽY•wl‰ÈŠw‰ïŠÖ“Œ˜A‡’n•û•”‰ï‘‰ïC‘å‹{C2000, 10. ‹{é‰xŽqFu‰‰uX”NŠúƒZƒ~ƒi[`‚±‚ê‚©‚çƒXƒeƒL‚ÈK”NŠú‚ð‚¨‚­‚邽‚ß‚É`v|‚ª‚ñгŽÒ‚³‚ñ‚Ìf—Âð’Ê‚µ‚Ä|D‚©‚È‚ª‚팒Nà’cu‰‰‰ïC‰¡•lC2000, ‚V. ‹{é‰xŽqF•wl‰È—̈æ‚É‚¨‚¯‚é’SŠà’·Šú¶‘¶Ç—áC”ÓŠúÄ”­Ç—á‚ÌŒŸ“¢|гŽÒ‚ÌQOL‹y‚Ñf—Âð‚ß‚®‚é”–â‘è|D‘æ‚P‰ñ‚©‚È‚ª‚팧—§•a‰@‚ª‚ñŒ¤‹†Šî‹à•¬‚É‚æ‚錤‹†•ñ‰ïC‰¡•lC2000, 9. ‹{é‰xŽqC’‡‘òŒo•vC’Å–¼DCÀè—ߎqC“c’†@–ôC–k‘º˜a‹vCˆîŽR‰Ã–¾C’†’Js—YC¬–죗ºC•½Œ´ŽjŽ÷FŽq‹{‘ÌŠà‚É‚¨‚¯‚é• o“à×–Ef‚ÌŒŸ“¢D‘æ39‰ñ“ú–{—Õ°×–EŠw‰ïHŠú‘å‰ïC‘å‹{C2000, 11. ‹{é‰xŽqFX”NŠú‚ð‚¢‚«‚¢‚«‚Æ‚·‚²‚·‚½‚ß‚É`•wl‰Èf—Â̌»ê‚©‚ç`D“’‰ÍŒ´’¬•ÛŒ’ƒZƒ“ƒ^[X”NŠúƒZƒ~ƒi[C“’‰ÍŒ´C2000, 11. ‹{é‰xŽqFŽq‹{Œz‚ª‚ñ‚̎戵‚¢‚ɂ‚¢‚ÄD‹à‘ò‹æŽY•wl‰Èˆã‰ïŠwpu‰‰‰ïC‰¡•lC2000, 11. ‹e’nއ’ÃŽqC•ˆä”üéC—é–Ø—ŠGC‘òˆä‚©‚¨‚èC’¬“c–«•¶C‘ê“¿—YFŋߌoŒ±‚µ‚½–¢nŠïŒ`Žî‚ÌÇ—áD‘æ‚Q‰ñ_“Þì•wl‰ÈŽîᇌ¤‹†‰ïC‰¡•lC2000, 9. ™‰Y@Œ«CˆÀ“¡‹IŽqC‘òˆä‚©‚¨‚èCÎŽR–¾”üC—é–Ø—ŠGC‹e’nއ’ÃŽqC•½Œ´ŽjŽ÷C•½’m—YF•êe‚ɋωqŒ^“]À‚Ì‚ ‚é•sˆç•v•w‚ÌÇ—á|ˆâ“`‘Š’k‚ð‚ß‚®‚Á‚Ä|D‘æ24‰ñ“ú–{—Õ°ˆâ“`Šw‰ïC‘åãC2000, 5. ™‰Y@Œ«C”ª“c[ŽqC¬–죗ºC‰Á“¡‹v·C’†ŽR—TŽ÷C‹{é‰xŽqC’‡‘òŒo•vC¼‰ºŒaLC“y‹‘å—SF“–‰È‚É‚¨‚¯‚郌[ƒU[‰~Øœp‚ÌŒŸ“¢D‘æ29‰ñ“ú–{•wl‰ÈŽîᇊw‰ïC–¼ŒÃ‰®C2000, 7. ™‰Y@Œ«C‹{é‰xŽqC”ª“c[ŽqC¼‰ºŒaLC’‡‘òŒo•vC¬–죗ºC‰Á“¡‹v·C’†ŽR—TŽ÷FƒŒ[ƒU[‚É‚æ‚é‰~Øœp‚ÌŒŸ“¢|Žå‚ÉŒzŠÇ‹·ó‚ɂ‚¢‚ÄD‘æ38‰ñ“ú–{ŠàŽ¡—Êw‰ïCå‘äC2000, 10. ™‰Y@Œ«C”ª“c[ŽqC¬–죗ºC‰Á“¡‹v·C’†ŽR—TŽ÷C¼‰ºŒaLC“y‹‘å—SC‹{é‰xŽqC’‡‘òŒo•vFŽq‹{èò•”×–Ef‚ÉoŒ»‚µ‚½“]ˆÚ«‚¨‚æ‚Ñ• o“àˆ««Žîá‡40—á ‚ÌŒŸ“¢D‘æ39‰ñ“ú–{—Õ°×–EŠw‰ïHŠú‘å‰ïC‘å‹{C2000, 11. ’ƒ–Ø@CCŒÜ—ˆˆí—YC‘P•û—T”üC–]ŒŽ‹v”üC‹e’n—¥ŽqC•½Œ´ŽjŽ÷F”A’†õ¿Œ^ƒRƒ‰[ƒQƒ“‰Ë‹´N––’[ƒyƒvƒ`ƒhiNTxj’l‚É‚æ‚é«—ˆ‚Ìœ—Ê—\‘ªD‘æ21‰ñ_“ÞìCaEœ‘ãŽÓŒ¤‹†‰ïC‰¡•lC2000, 1. ’ƒ–Ø@CCŒÜ—ˆˆí—YC‘P•û—T”üC‹e’n—¥ŽqC•½Œ´ŽjŽ÷Fƒzƒ‹ƒ‚ƒ“•â[—Ö@‚É‚æ‚霖§“x‚Æœ‘ãŽÓƒ}[ƒJ[•Ï“®‚Ì‘½—l«D‘æ52‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ïC“¿“‡C2000, 4. ’ƒ–Ø@CCŒÜ—ˆˆí—YC‘P•û—T”üC‹e’n—¥ŽqC–]ŒŽ‹v”üC•½Œ´ŽjŽ÷F‚—î—«‚É‚¨‚¯‚éƒGƒXƒgƒƒQƒ“•â[—Ö@‚Ìœ‚ɑ΂·‚éŒø‰Ê|•ÂŒo’¼Œã—«‚Ƃ̔äŠrEŒŸ“¢|D‘æ18‰ñ“ú–{œ‘ãŽÓŠw‰ïCL“‡C2000, 7. ’ƒ–Ø@CCŒÜ—ˆˆí—YC‘P•û—T”üC‹e’n—¥ŽqC’†ŽR¹Ž÷C•½Œ´ŽjŽ÷Fœ‹zŽûƒ}[ƒJ[GNTx‚Í‚R”NŒã‚܂Ř’Åœ—ʂ̕ω»‚ð—\‘ª‚Å‚«‚éD‘æ15‰ñ“ú–{X”NŠúˆãŠw‰ïŠwpW‰ïCŽD–yC2000, 10. ’ƒ–Ø@CCŒÜ—ˆˆí—YC–]ŒŽ‹v”üC‘P•û—T”üC‹e’n—¥ŽqC•½Œ´ŽjŽ÷Fœ‘ãŽÓƒ}[ƒJ[‚É‚æ‚èƒzƒ‹ƒ‚ƒ“•â[—Ö@‚¨‚æ‚ÑBisphosphonate—Ö@Žž‚Ìœ—ʂɑ΂·‚éŒø‰Ê‚Í—\‘ª‚Å‚«‚é‚©D‘æ‚Q‰ñ“ú–{œ‘eé ÇŠw‰ïCH“cC2000, 10. ’ƒ–Ø@CCŒÜ—ˆˆí—YC–]ŒŽ‹v”üCr“c—^ŽuŽqC‘P•û—T”üC‹e’n—¥ŽqC•½Œ´ŽjŽ÷F•ÂŒoŒã—«‚̒᜗ʂ¨‚æ‚Ñœ‘eé Ç‚ÌŽ¡—Ö@‚Ì”äŠrEŒŸ“¢|œ–§“x‘ª’è‚Æœ‘ãŽÓƒ}[ƒJ[‚ð—p‚¢‚½‰ðÍ|D‘æ11‰ñ•wl‰Èœ‘eé ÇŒ¤‹†‰ïC“Œ‹žC2000, 11. ‹´–{@‰hC›Œ´’qCÂŽR”ü‰ÁC󌩭rC•½’m—YF”DP26T–¢–ž‚Å•ê‘Ì”À‘—‚³‚ꂽǗá‚ɂ‚¢‚Ă̌Ÿ“¢DŽY‰È‹~‹}˜A—‰ïC‰¡•lC2000, 7. ‰F“cìDC’‡‘òŒo•vCÀè—ߎqC“c’†@–ôC‹{é‰xŽqC¬–죗ºCˆîŽR‰Ã–¾C’†’Js—YC•½Œ´ŽjŽ÷F–UŒŸŽž‚É”»–¾‚µ‚½ˆÝŠà‡•¹Žq‹{èòŠà‚Ì‚PÇ—áD‘æ41‰ñ“ú–{—Õ°×–EŠw‰ï‘‰ïC“Œ‹žC2000, ‚U. ÂŽR”ü‰ÁC•½’m—YCŽR’†”ü’qŽqF•¡ŽGSŠïŒ`‚𔺂¤‘½äBÇŒóŒQE–³äBÇŒóŒQ‚Ìo¶‘O’´‰¹”gf’f‚Æ‚»‚Ì’mD‘æ24‰ñ“ú–{—Õ°ˆâ“`Šw‰ïC‘åãC2000, 5. ‰¡ˆä‰ÄŽqC‹ß“¡–FmC‚“‡–M—»C‘º£^—ŽqC¼–{‰Á‘ãCÎì‰ë•FC’r“c–œ—¢˜YC•½Œ´ŽjŽ÷CA‘ºŽŸ—YFŽ‹°‰º•”«‘æ“ñ“x–³ŒŽŒo‚É‚¨‚¯‚éhMG-GnRH—¥“®“I“Š—^‚É‚æ‚é”r—‘—U”­–@‚ÌŒŸ“¢‚Æ‚»‚̉ü—ǂɂ‚¢‚ÄD‘æ52‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ïC“¿“‡C2000, 4. ‰¡ˆä‰ÄŽqC‘qàVŒ’‘¾˜YC–]ŒŽ‹v”üC‘å’ëM²C–Γc”ŽsC’·“c‹v•¶FŽq‹{ŠïŒ`‚𔺂Á‚½Žá”NŽq‹{“à–ŒÇ‚Ì‚P—áD‘æ352‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ïC‘æ101‰ñ•ª•؂ƖƒŒŒ¤‹†‰ïC‰¡•lC2000, 12. ²“¡”ü‹IŽqC’r“c–œ—¢˜YC‘½‰ê—‹gC•½Œ´ŽjŽ÷CHovey RCCVonderhaar BKFV¶Ž™Šú‚ÉDiethylstilbestroliDESj–”‚ÍTamoxifeniTAMj‚É–\˜I‚³‚ꂽƒ}ƒEƒX“û‘B‚Ì«ƒXƒeƒƒCƒh‚ɑ΂·‚锽‰ž«•ω»D‘æ‚X‰ñŽY•wl‰È•ªŽq“à•ª”姘b‰ïC‹ž“sC2000, 11. ›Œ´’qCÂŽR”ü‰ÁC‹´–{@‰hC󌩭rC•½’m—YCŽR’†”ü’qŽqF–ƒ]Š´õŒã‚É‘o‘ÙˆêŽ™Ž€–S‚ƂȂÁ‚½Ç—áD‘æ352‰ñ_“Þ쌧ŽY•wl‰È’n•û•”‰ïC‰¡•lC2000, 12. “c’†@–ôC’Å–¼DC“c’†–¾ŽqC‹{é‰xŽqC’‡‘òŒo•vCŒÜ—ˆˆí—YC•½Œ´ŽjŽ÷F“–‰È‚ɉ—‚¯‚éãO–Ñ«Ž¾Š³‚ÌŽ¡—ìтɂ‚¢‚ÄD‘æ38‰ñ“ú–{ŠàŽ¡—Êw‰ïCå‘äC2000, 10. ¼–{‰Á‘ãC匴G–çC‹ß“¡–FmC•½Œ´ŽjŽ÷F“–‰È‚É‚¨‚¯‚鬎™EŽvtŠú—«ŽófŽÒ‚Ì—Õ°“IŒŸ“¢D‘æ19‰ñ“ú–{ŽvtŠúŠw‰ïC“Œ‹žC2000, ‚W. ‘º£^—ŽqC‹ß“¡–FmCÎŽR•ü”üCÎì‰ë•FC’r“c–œ—¢˜YC•½Œ´ŽjŽ÷FƒNƒbƒVƒ“ƒOÇŒóŒQ‚Ƃ̊ӕʂɓïa‚µ‚½‘½”X–E«—‘‘ƒÇŒóŒQ‚ÌÇ—áD‘æ100‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠÖ“Œ˜A‡’n•û•”‰ï‘‰ïC‘å‹{C2000, 10. “c’†–¾ŽqC–Γc”ŽsC_“c‹`–¾C‹g“c@_C™‰Y@Œ«C’·“c‹v•¶FŽq‹{‹ØŽî‚É‚æ‚é‚“x•nŒŒiHb 1.3g/dlj‚É‚æ‚èS”x’âŽ~‚𗈂µ‚½‚ªC‹~–½‚µ“¾‚½ˆê—áD‘æ348‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ïC‰¡•lC2000, 5. “c’†–¾ŽqC’‡‘òŒo•vC‰F“cìDC‹{é‰xŽqC•½Œ´ŽjŽ÷F“–‰@•wl‰È‚É‚¨‚¯‚郂ƒ‹ƒqƒlŽg—p󋵂̌Ÿ“¢|‰ß‹Ž9”NŠÔ‚ÌÇ—á‚ðU‚è•Ô‚Á‚Ä|D‘æ‚T‰ñ“ú–{ŠÉ˜aˆã—Êw‰ïCŒF–{C2000, 6. “c’†–¾ŽqC’†ŽR¹Ž÷Cˆä”¨@âtC‘å’ëM²C匴G–çC”’{˜a—TC²“¡Œ[Ž¡C•½Œ´ŽjŽ÷F”ZŒúÔŒŒ‹…—AŒŒ‚ªŒ´ˆö‚Æl‚¦‚ç‚ꂽ—AŒŒŠÖ˜A‹}«”xáŠQ‚Ì‚P—áD‘æ99‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠÖ“Œ˜A‡’n•û•”‰ïC“Œ‹žC2000, 6. “c’†–¾ŽqC¼–{‰Á‘ãC‹ß“¡–FmC匴G–çC•½Œ´ŽjŽ÷F“–‰È‚É‚¨‚¯‚éŽá”NŽÒ‚ÌŽîá‡«Ž¾Š³‚ÌŒ»óD‘æ19‰ñ“ú–{ŽvtŠúŠw‰ïC“Œ‹žC2000, ‚W. ‹g“c@_C匴G–çC‘å‰Í“àç’ߎqCA‘ºŽŸ—YC‘½‰ê—‹gC•½Œ´ŽjŽ÷FGnRHƒjƒ…[ƒƒ“‚É‚¨‚¯‚écyclic nucleotide phosphodiesteraseiPDEjsubtype‚Ì”­Œ»‚ÆGnRH•ª”å’²®‚É‚¨‚¯‚éˆÓ‹`D‘æ23‰ñ“ú–{_Œo‰ÈŠw ‘å‰ïC‘æ10‰ñ“ú–{_Œo‰ñ˜HŠw‰ï@‡“¯‘å‰ïC‰¡•lC2000, 9. —é–Ø—ŠGC’¬“c–«•¶C•ˆä”üéC‹e’nއ’ÃŽqC‘òˆä‚©‚¨‚èC‘ê“¿—YC‘P•û‹e•vC‘P•û—T”üF”DP38T‚ÅŽq‹{“à‘ÙŽ™Ž€–SiIUFDj‚𗈂½‚µ‹}«‘ˆ«‚µ‚½“œ”A•a«ƒPƒgƒAƒVƒh[ƒVƒX‚Ì‚P—áD‘æ100‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠÖ“Œ˜A‡’n•û•”‰ï‘‰ïC‘å‹{C2000, 10. —é–Ø—ŠGC’¬“c–«•¶C•ˆä”üéC‹e’nއ’ÃŽqCކ’Jß•vC‘ê“¿—YF—‘ŠÇ—¯…Žî”P“]‚̈ê—áD‘æ348‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ïC‰¡•lC2000, 5. –]ŒŽ‹v”üC’ƒ–Ø@CC‘P•û—T”üC‹e’n—¥ŽqCŒÜ—ˆˆí—YC•½Œ´ŽjŽ÷Fƒzƒ‹ƒ‚ƒ“•â[—Ö@’†‚É”­Œ©‚³‚ꂽ—‘‘ƒ‚ª‚ñ‚̈ê—áD‘æ15‰ñ“ú–{X”NŠúˆãŠw‰ïCŽD–yC2000, 10. ˆä”¨âtC‚“‡–M—»C¼ˆä_ŽuC’†ŽR¹Ž÷C”’{˜a—TC²“¡Œ[Ž¡Fˆ««Žîᇇ•¹”DP‚Ì‚S—áD‘æ351‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ïC‰¡•lC2000, 11. ‹ß“¡@KC‘åŽRrŽ÷C–Ñ—˜@‡CA‘ºŽŸ—YF•úŽËü—Ö@‚ª’˜Œø‚µ‚½endometrial stromal sarcoma, high grade‚̈ê—áD‘æ346‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ïCìèC2000, 2. ‹ß“¡@KCt–Ø@“ÄCÎì_ŽjCˆÀ“¡‹IŽqC‚‹´P’jC‰““¡•ûÆC•½Œ´ŽjŽ÷F•ª•ØŽž‚ɑَ™•p–¬‚ð”F‚ß‚½Ç—áD‘æ16‰ñ•ª•ØŠÄŽ‹Œ¤‹†‰ïC“Œ‹žC2000, 11. ²Ž¡°ÆCŠâ‹´˜aŽqCÂŽR”ü‰ÁC󌩭rC•½’m—YCŽR’†”ü’qŽqFƒƒTƒ‹ƒ^ƒ“ƒJƒŠƒEƒ€‚Ì•ê‘Ì“Š—^’†‚É—r…‰ß­Ç‚𗈂½‚µCŽq‹{“à‘ÙŽ™Ž€–S‚ƂȂÁ‚½ˆê—áD‘æ52‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ïC“¿“‡C2000, 4. ‚“‡–M—»CÎì‰ë•FC‹ß“¡–FmC‘º£^—ŽqC’r“c–œ—¢˜YC•½Œ´ŽjŽ÷FŽq‹{ŠO”DP‚ɑ΂·‚é• o‹¾‰ºŽèp‚ÆŽ©‘RŽ¡–ü‘Ò‹@—Ö@‚ɂ‚¢‚Ă̌Ÿ“¢D‘æ45‰ñ“ú–{•s”DŠw‰ïC_ŒËC2000, 11. ‚“‡–M—»CÎì‰ë•FC‹ß“¡–FmCÎŽR•ü”üC‘º£^—ŽqC‰¡ˆä‰ÄŽqC’r“c–œ—¢˜YC•½Œ´ŽjŽ÷FŽq‹{ŠO”DP‚ɑ΂·‚é• o‹¾‰ºŽèp‚ÆŽ©‘RŽ¡–ü‘Ò‹@—Ö@‚ɂ‚¢‚Ă̌Ÿ“¢D‘æ46‰ñ“ú–{•s”DŠw‰ï‘‰ïC“Œ‹žC2000, 11. _“c‹`–¾C–Γc”ŽsC“c’†–¾ŽqC‹g“c@_C™‰Y@Œ«C’·“c‹v•¶FCA125‚ª‚’l‚ðŽ¦‚µ‚½MeigsÇŒóŒQ‚̈ê—áD‘æ346‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ïCìèC2000, 2. _“c‹`–¾Ct–Ø@“ÄCÎì_ŽjCˆÀ“¡‹IŽqC‚‹´P’jC‰““¡•ûÆC•½Œ´ŽjŽ÷FíˆÊ‘Ù”Õ‘Šú”—£‚ÌŒŸ“¢D‘æ15‰ñ•ª•ØŠÄŽ‹Œ¤‹†‰ïC“Œ‹žC2000, ‚U. _“c‹`–¾Ct–Ø@“ÄCÎì_ŽjCˆÀ“¡‹IŽqC‚‹´P’jC‰““¡•ûÆC•½Œ´ŽjŽ÷FíˆÊ‘Ù”Õ‘Šú”—£Ç—á‚ÌŒŸ“¢D‘æ100‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠÖ“Œ˜A‡’n•û•”‰ï‘‰ïC‘å‹{C2000, 10. ”’ˆä@ÊC’¬“c–«•¶C—é–Ø—ŠGC‹e’nއ’ÃŽqCކ’Jß•vC‘ê“¿—YFŽq‹{‘Ì•”މ–b•½ŠŠ‹ØŽî‚̈ê—áD‘æ345‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ïC‰¡•lC2000, 1. ×ì^—ŽqC²Ž¡³•FCŽR‰ê–¾OC‚ˆÀ‹`OF“–‰@‚É‚¨‚¯‚éƒAƒ‹ƒSƒ“ƒr[ƒ€ƒRƒAƒMƒ…ƒŒ[ƒ^[‚ð—p‚¢‚½‰~ØœpD‘æ348‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ïC‰¡•lC2000, 5. ‘qàVŒ’‘¾˜YC“c’†–¾ŽqC_“c‹`–¾C‹g“c@_C™‰Y@Œ«C–Γc”ŽsC’·“c‹v•¶Fæ“V«•›t‰ßŒ`¬‡•¹”DP‚̈ê—áD‘æ99‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠÖ“Œ˜A‡’n•û•”‰ïC“Œ‹žC2000, 6. ‘qàVŒ’‘¾˜YC‹g“c@_C–Γc”ŽsC’·“c‹v•¶FƒJƒ‹ƒ`ƒmƒCƒhÇŒóŒQ‚ð’æ‚µ‚½—‘‘ƒŒ´”­ƒJƒ‹ƒ`ƒmƒCƒh‚̈ê—áD‘æ100‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠÖ“Œ˜A‡’n•û•”‰ï‘‰ïC‘å‹{C2000, 10. •ˆä”üéC—é–Ø—ŠGC‹e’nއ’ÃŽqC‘òˆä‚©‚¨‚èC’¬“c–«•¶C‘ê“¿—YFƒoƒ‹ƒgƒŠƒ“‘B—R—ˆ‚Æl‚¦‚ç‚ꂽG•½ã”çŠà‚Ì‚P—áD‘æ349‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ïC‘Š–ÍŒ´C2000, 7. •ˆä”üéC’¬“c–«•¶C—é–Ø—ŠGC‹e’nއ’ÃŽqC‘òˆä‚©‚¨‚èC‘ê“¿—YFŽYåñŽqᒌ㑽‘ŸŠí•s‘S‚ð‚«‚½‚µICUŠÇ—‚ð—v‚µ‚½ˆê—áD‘æ351‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ïC‰¡•lC2000, 11. ’·£Š°”üC‘åŽRrŽ÷C–Ñ—˜@‡CA‘ºŽŸ—YCç—tŠì”ü’jCLìMFGnRHƒAƒSƒjƒXƒg‚𔽕œ“Š—^‚µ‚½Žq‹{“à–ŒÇ‚É‚æ‚é…tǂ̈ê—áD‘æ100‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠÖ“Œ˜A‡’n•û•”‰ï‘‰ïC‘å‹{C2000, 10. ‚@–Ö‰ÌCA‘ºŽŸ—YCˆî“c^ˆ¤C‘º£^—ŽqC‹ß“¡–FmC匴G–çC•½Œ´ŽjŽ÷F‹Ž¨Ž“ƒ‰ƒbƒg‚É‚¨‚¯‚éGnRH antagonistiGnRHantj‚ÌGnRH receptor mRNA, LHb subunit mRNA‚É‹y‚Ú‚·‰e‹¿‚ɂ‚¢‚ÄD‘æ52‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ïC“¿“‡C2000, 4. ‹à@–¾ŽõC‰F“cìDC‹{é‰xŽqC’‡‘òŒo•vC•½Œ´ŽjŽ÷CˆÀŒõ‰p‘¾˜YC‹{è@C’·“ˆ—mŽ¡C–؈ê˜YCŒ´“c¹‹»C‹{é—m•½FƒZƒŠƒ“ƒvƒƒeƒA[ƒ[ƒCƒ“ƒqƒrƒ^[PP5/ TFPI-2‚É‚æ‚éãO–ÑŠà×–E‚ÌZ”\—}§D‘æ59‰ñ“ú–{ŠàŠw‰ï‘‰ïC‰¡•lC2000, 10. •ž•”—T‰îC‘º£^—ŽqCÎì‰ë•FC‹ß“¡–FmCÎŽR•ü”üC_“c‹`–¾C’r“c–œ—¢˜YCÎì_ŽjCˆÀ“¡‹IŽqC‚‹´P’jC“c’†–¾ŽqC•½Œ´ŽjŽ÷F”DP‰Šú‚É”xÇðǂ𔭶‚µ‚½‹‘åŽq‹{‹ØŽî‚Ì‚P—áD‘æ351‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ïC‘æ42‰ñ_“ÞìˆãŠw‰ï‘‰ïŽY•wl‰È•ª‰È‰ïC‰¡•lC2000, 11. ‰¡“c“Þ•üC’ƒ–Ø@CC“c’†@–ôCÀè—ߎqC‰F“cìDC’‡‘òŒo•vCŒÜ—ˆˆí—YC’†’Js—YC•½Œ´ŽjŽ÷F¬’°Œ´”­KrukenbergŽîᇂ̈ê—áD‘æ99‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠÖ“Œ˜A‡’n•û•”‰ïC“Œ‹žC2000, 6. ’†ŽR—TŽ÷C”ª“c[ŽqC‹{é‰xŽqC¬–죗ºC‰Á“¡‹v·C“c‘º@–ÒC“y‹‘å—SC’‡‘òŒo•vFŠO’•W–{‚Ì’áõF«‚͉½‚É‹Nˆö‚·‚é‚Ì‚©ÌŽæE“h–•EŒÅ’è–@‚É‚æ‚éŽÀŒ±“IŒŸ“¢D‘æ41‰ñ“ú–{—Õ°×–EŠw‰ï‘‰ïC“Œ‹žC2000, ‚U. ’†ŽR—TŽ÷C”ª“c[ŽqC™‰Y@Œ«C¬–죗ºC‰Á“¡‹v·FŽq‹{‘ÌŠà“]ˆÚ‚Ì•a‘Ô‚ÆŽ¡—ÃŒø‰ÊD‘æ29‰ñ“ú–{•wl‰ÈŽîᇊw‰ïC–¼ŒÃ‰®C2000, 7. ’†ŽR—TŽ÷C”ª“c[ŽqC™‰Y@Œ«C¬–죗ºC‰Á“¡‹v·C¼‰ºŒaLC‹{é‰xŽqF“–‰È‚É‚¨‚¯‚épaclitaxelCCBDCA•¹—p—Ö@‚ÌŒø‰Ê‚Æ•›áŠQD‘æ38‰ñ“ú–{ŠàŽ¡—Êw‰ïCå‘äC2000, 10. ’†ŽR—TŽ÷C”ª“c[ŽqC™‰Y@Œ«C¬–죗ºC‰Á“¡‹v·C¼‰ºŒaLC“y‹‘å—SC‹{é‰xŽqC’‡‘òŒo•vF•wl‰È×–Ef¸“xŒüã‚Ì‚½‚߂̎{ô‚ðÄŒŸ“¢‚·‚éÌŽæ‚©‚çõF‚܂ł̌»ó‚Æ–â‘è“_D‘æ39‰ñ“ú–{—Õ°×–EŠw‰ïHŠú‘å‰ïC‘å‹{C2000, 11. ‰Á“¡‹v·C”ª“c[ŽqC‹{é‰xŽqC¬–죗ºC¼‰ºŒaLC“y‹‘å—SC’‡‘òŒo•vC’†ŽR—TŽ÷F•ÂŒoŒã‚ÌŽq‹{èò•”ˆÙŒ`¬‚ÌŠÇ—C‚¨‚æ‚Ñ’·Šú’ÇÕ—á‚ÌŒŸ“¢D‘æ41‰ñ“ú–{—Õ°×–EŠw‰ï‘‰ïC“Œ‹žC2000, ‚U. ‰Á“¡‹v·C”ª“c[ŽqC™‰Y@Œ«C¬–죗ºC’†ŽR—TŽ÷C—›—´•PF“–‰È‚ÅŒoŒ±‚µ‚½ŠO‰AŠà52—á‚Ì—Õ°•a—Šw“IŒŸ“¢D‘æ29‰ñ“ú–{•wl‰ÈŽîᇊw‰ïC–¼ŒÃ‰®C2000, 7. ‰J‹{@´C’·“c‹v•¶C‰Á“¡—ÇŽ÷C–Ø‘ºº—TC¬¼‰pŠìC–Ø”ÒvŽœCÖ“¡Š]C‚‹´‹œ³C“c“‡•q‹vC’‡‘òŒo•vC’†ŽR—TŽ÷C`@GŽ÷C‘ºã@—DC–ö‘ò˜aFF_“Þ쌧‚É‚¨‚¯‚éãO–Ñ«Ž¾Š³”­¶ó‹µ|‰ß‹Ž‚RŠúŠÔ‚Ì“o˜^󋵂̔äŠrŒŸ“¢D‘æ18‰ñãO–Ñ«Ž¾Š³Œ¤‹†‰ïCŽD–yC2000, 8. ㌴‹v”üC¼–{‰Á‘ãC’Å–¼DC‹{é‰xŽqC’‡àVŒo•vCŒÜ—ˆˆí—YC•½Œ´ŽjŽ÷C’†’Js—YF’Ž‚Šà‚ð‡•¹‚µ‚½Žq‹{èò•”ˆ««‘BŽî‚Ì‚P—áD‘æ349‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ïC‘Š–ÍŒ´C2000, 7. ‘¾“cˆê˜YCŒÜ—ˆˆí—YC’‡‘òŒo•vC•½Œ´ŽjŽ÷F—‘‘ƒ–¾×–EŠà‚ÆŸ÷‰t«“û“ªó‘B×–EŠ”‚ð—p‚¢‚½RŠà‰»Šw—Ö@‚ÌŒ¤‹†iõ¿jD‘æ52‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ïC“¿“‡C2000, 4. ‘¾“cˆê˜YCŒÜ—ˆˆí—YC•½Œ´ŽjŽ÷C镸ˆêF‰–Ž_ƒCƒŠƒmƒeƒJƒ“‚Æ‚T|ƒtƒ‹ƒIƒƒEƒ‰ƒVƒ‹—‘‘ƒŠà×–EŠ”‚ɑп“I‚Éì—p‚·‚éD‘æ59‰ñ“ú–{ŠàŠw‰ï‘‰ïC‰¡•lC2000, 10. ‰ªèr”VC‘¾“cˆê˜YCŒÜ—ˆˆí—YC’‡‘òŒo•vC•½Œ´ŽjŽ÷C镸ˆêF—‘‘ƒ–¾×–E‘BŠà‚ɑ΂·‚鉻Šw—Ö@‚ÌŠî‘b“IŒ¤‹†`‘gDŒ^‚ÉŠî‚Â­Š´Žó«‚Æ‘½Ü•¹—p—Ö@‚ÌŒŸ“¢`D‘æ120‰ñ“ú–{–òŠw‰ïCŠò•ŒC2000, 3. ‰½@“¿‹ÔC”ü’Ó‡‘åCA‘ºŽŸ—YC•½Œ´ŽjŽ÷C‹M—W•y‹vŽqF—Y«ƒ‰ƒbƒg‚É‚¨‚¯‚éGABAAŽó—e‘Ì—z«GnRHƒjƒ…[ƒƒ“”‚Ì”­’B•ω»D‘æ77‰ñ“ú–{¶—Šw‰ïC‰¡•lC2000, 3. {ŽRg”üŽqCät‹´—˜–çCA‘ºŽŸ—YC•½Œ´ŽjŽ÷C‹M—W•y‹vŽqFŽ‹°‰º•”•sŽ€‰»GnRHƒjƒ…[ƒƒ“iGT1-7×–Ej‚Ì“d‹CŠˆ“®‚Ì‘½“_“¯Žž‹L˜^D‘æ77‰ñ“ú–{¶—Šw‰ïC‰¡•lC2000, 3. {ŽRg”üŽqCät‹´—˜–çC‹M—W•y‹vŽqC•½Œ´ŽjŽ÷CA‘ºŽŸ—YFGnRHƒjƒ…[ƒƒ“iGT1-7×–Ej‚Ì“d‹CŠˆ“®‚ɑ΂·‚éƒGƒXƒgƒƒQƒ“‚ÆNMDA‚Ì‘ŠŒÝì—pF‘½“d‹É”|—{ŽMiMEDj‚ð—p‚¢‚½ŒŸ“¢D‘æ‚T‰ñ“ú–{¶B“à•ª”åŠw‰ïC–L’†C2000, 12. “c‘º“ÖŽqC–]ŒŽ‹v”üC‰““¡•ûÆCˆÀ“¡‹IŽqC‚‹´P’jC‘½‰ê—‹gC•½Œ´ŽjŽ÷FĶ•s—Ç«•nŒŒ‡•¹”DP‚̈ê—áD‘æ346‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ïC‰¡•lC2000, 2. ’†–ì^²’jCˆÀ“¡‹IŽqC“à“cLOC™@r—²C—é–Ø^CŠÖ’J—²•vC“cŒû–¾C“c’†²C’†‘º‰p¢C”‹’ëˆêŒ³C•y‹v”öMC‹gŒ´@ˆêCˆË“c@‹ÅCZ‹gD—YC²“¡Œ[Ž¡C‚‹´P’jCŽR’†”ü’qŽqF_“Þì‚É‚¨‚¯‚鑽‘Ù”DP‚Ì”­¶‚Æ•ª•؂̎À‘ÔD‘æ351‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ï_“Þì’n•û•”‰ïC‘æ42‰ñ_“ÞìˆãŠw‰ï‘‰ïŽY•wl‰È•ª‰È‰ïC‰¡•lC2000, 11. ”ª“c[ŽqC‰Á“¡‹v·C‹{é‰xŽqC¬–죗ºC¼‰ºŒaLC“y‹‘å—SC’‡‘òŒo•vC‰ª“‡OKC’†ŽR—TŽ÷F‚æ‚èׂ¢“à–Œ‹zˆø×–EfÌŽæŠí‹ïu‘½EƒfƒCƒLƒƒƒXv‚ÌŠJ”­‚Æ—L—p«‚ÌŒŸ“¢D‘æ41‰ñ“ú–{—Õ°×–EŠw‰ï‘‰ïC“Œ‹žC2000, ‚U. ”ª“c[ŽqC¼‰ºŒaLC™‰Y@Œ«C¬–죗ºC‰Á“¡‹v·C’†ŽR—TŽ÷FŽq‹{‘ÌŠàŠg‘åŽèp‚ÌŒø‰Ê‚ÆƒŠƒXƒND‘æ38‰ñ“ú–{ŠàŽ¡—Êw‰ïCå‘äC2000, 10. ”ª“c[ŽqC™‰Y@Œ«C¬–죗ºC‰Á“¡‹v·C’†ŽR—TŽ÷C¼‰ºŒaLC“y‹‘å—SC‹{é‰xŽqC’‡‘òŒo•vFŽq‹{‘Ì•”–¾×–E‘BŠà‚Ì×–E‘œ‚ÌŒŸ“¢D‘æ39‰ñ“ú–{—Õ°×–EŠw‰ïHŠú‘å‰ïC‘å‹{C2000, 11. •zŽ{‹žŽqC“c’†P–¾C‰Á‰ê’J”£C—é–Ø@–ÒC–Ø‘ºº—TF—‘‘ƒŠà‚É‚¨‚¯‚éƒpƒNƒŠƒ^ƒLƒZƒ‹/ƒJƒ‹ƒ{ƒvƒ‰ƒ`ƒ“weekly“Š—^‰º‚ł̕›ì—p‚ÌŒŸ“¢D‘æ10‰ñ“ú–{•a‰@–òŠw‰ïC‹ž“sC2000, 10. ¼‰ºŒaLC‹{é‰xŽqC¬–죗ºC‰Á“¡‹v·C’†ŽR—TŽ÷C”ª“c[ŽqC“y‹‘å—SC’‡‘òŒo•vC‰ª“‡OKF‚æ‚èׂ©‚¢“à–Œ‹zˆø×–EfÌŽæŠí‹ïu‘½EƒfƒCƒLƒƒƒXv‚ÌŠJ”­‚Æ—L—p«‚ÌŒŸ“¢D@‘æ52‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ïC“¿“‡C2000, 4.
iŒ¤‹†•¬‹àj Œú¶È •½Œ´ŽjŽ÷i‘ãjFŒú¶‰ÈŠwŒ¤‹†,@“ú•êŠO•\ŠïŒ`“™’²¸‹y‚Ñ–{–M‚É‚¨‚¯‚éæ“VˆÙí‚ÉŠÖ‚·‚錤‹†C150–œ‰~. •½Œ´ŽjŽ÷i•ªjFŒú¶‰ÈŠwŒ¤‹†Cˆâ“`ˆã—ÃVƒXƒeƒ€‚Ì\’z‚Ɖ^—p‚ÉŠÖ‚·‚錤‹†C20–œ‰~. Z‹gD—Yi‘ãjFŒú¶‰ÈŠwŒ¤‹†,@æ“VˆÙ탂ƒjƒ^ƒŠƒ“ƒO‚ÉŠÖ‚·‚錤‹†,@900–œ‰~. •¶•”È •½Œ´ŽjŽ÷i‘ãjF—‘‘ƒ‚ª‚ñ‚ÌZ“]ˆÚ‹@\‚É‚¨‚¯‚éƒgƒŠƒvƒVƒ“‚Ì–ðŠ„‚ÉŠÖ‚·‚錤‹†CŠî”ÕCC150–œ‰~. •½Œ´ŽjŽ÷i•ªjFŒûOŒûŠW—ô”­Œ»‚Æ•ê‘̊‹«—vˆö‚ÉŠÖ‚·‚錤‹†CŠî”ÕAC30–œ‰~D •½Œ´ŽjŽ÷i•ªjFŒ´ˆö•s–¾•sˆçÇ‚ÆXõF‘Ì•sŠˆ‰»ƒpƒ^[ƒ“‚ÉŠÖ‚·‚é‰uŠw“IŒ¤‹†CŠî”ÕCC50–œ‰~D ‚‹´P’ji‘ãjFƒGƒXƒgƒƒQƒ“‚ÌŽq‹{“à–ŒŠà”­¶ì—p‚É‚¨‚¯‚éTGFƒÀ‚Ì–ðŠ„‚ÌŒ¤‹†CŠî”ÕCCV‹KC210–œ‰~D ’r“c–œ—¢˜Yi‘ãjF—‘‘ƒ‘gD‚Ì“€Œ‹•Û‘¶–@‚¨‚æ‚щ𓀌ã‚̊튯”|—{‚ł̗‘–EŽhŒƒ–@‚ÉŠÖ‚·‚錤‹†CŠî”ÕCC•½¬11”N“xŒp‘±C110–œ‰~D 匴G–çi‘ãjFƒCƒ“ƒ^[ƒtƒFƒƒ“‚É‚æ‚éƒqƒgŽq‹{“à–Œ‚Ì‘BE•ª‰»‚Ì’²®‹@\‚ÉŠÖ‚·‚錤‹†CŠî”ÕCCi•½¬14”N‚RŒŽ‚Ü‚ÅjC150–œ‰~D ŠÂ‹«’¡ Z‹gD—Yi‘ãjC•½Œ´ŽjŽ÷i•ªjF“à•ª”åŠh—‰»Šw•¨Ž¿‚Ìl‘̂ɋy‚Ú‚·‰e‹¿‚ÉŠÖ‚·‚錤‹†C828–œ‰~. ‚»‚Ì‘¼ Z‹gD—Yi‘ãjC•½Œ´ŽjŽ÷i•ªjFŠO•\ŠïŒ`“™æ“VˆÙ탂ƒjƒ^ƒŠƒ“ƒO•À‚Ñ‚Éæ“VˆÙí—\–hCæ“VˆÙíŽ™Ž¡—ÕÀ‚тɃtƒHƒ[‘̧‚ÌŠm—§‚ÉŠÖ‚·‚錤‹†C“ú•ꂨ‚¬‚á[Œ£‹à“Á•ʈϑõŒ¤‹†D300–œ‰~D ‹g“c@_i‘ãjFGonadotropin-releasing hormoneiGnRHjƒjƒ…[ƒƒ“‚©‚ç‚ÌGnRH•ª”å‚É‚¨‚¯‚écyclic nucleotide phosphodiesteraseiPDEj‚Ì–ðŠ„‚ÉŠÖ‚·‚錤‹†Cà’c–@l‰¡•lˆãŠwU‹»à’cˆê”ÊŒ¤‹†•¬C40–œ‰~D